Sector News

Money-back guarantees on cancer drugs are real in Italy

January 19, 2016
Life sciences

One country is ahead of the curve in striking pay-for-performance deals on cancer drugs–and, more importantly, collecting the cash when treatments don’t hit their goals.

That country is Italy, and its money-back guarantees on cancer drugs are sparking interest in the U.S. and elsewhere in Europe, Bloomberg reports. With more drugs fast-tracked through regulatory review, and many approved after preliminary data from small trials, Italy sees those money-back deals as a way to stay on the leading edge of treatment without breaking the bank on drugs that don’t work as promised.

The country’s medicines regulator had full-refund deals on more than 90 drugs by the end of 2014, up from less than 20 in 2012, Bloomberg says. Last year, it collected about 200 million euros ($220 million) under those money-back deals.

Italy also uses a strategy payers are studying in the U.S.: reimbursement and contracts that vary by cancer type. One drug might be fully refundable in one type of cancer and only partially rebated in another. The American Society of Clinical Oncology recently unveiled one framework for evaluating drugs cancer-by-cancer, and Express Scripts says it will experiment with the approach this year.

One difference in Italy is that the medicines agency there established national treatment registries in 2005 to track outcomes from various drugs. This system provides hard data for negotiating agreements and, with results continually coming in, a basis for renegotiating every couple of years. This sort of tracking is an important part of collecting refunds when and if they’re due.

As Bloomberg notes, Roche has been experimenting in France with tracking patient and treatment outcomes as a step toward more performance-based pricing. It’s not easy: The U.K., for one, has had trouble collecting on its few pay-for-performance reimbursement deals, according to a government report. And in the U.S., which lacks any kind of centralized health-records database, money-back deals could be even tougher. Amgen recently struck a pay-for-performance deal on its PCSK9 cholesterol drug Repatha, but it’s with Harvard Pilgrim Health Care, a small regional payer.

Both Roche CEO Severin Schwan and Novartis CEO Joe Jimenez have backed this sort of approach to reimbursement in recent months, and as the top two companies in oncology, their backing could be key to widespread adoption.

Novartis has pushed for performance-based deals on its heart failure drug Entresto–albeit not so successfully–and Jimenez recently told the French newspaper Le Temps that “money-back” pricing and other deals are “a way forward” through the pressure of rising drug prices. “The pharmaceutical industry will have to provide new approaches to pricing that will eliminate waste,” Jimenez said.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach